Increased potency and sustained suppressive actions of a new gonadotropin-releasing hormone (GnRH) antagonist peptide in man.

Randall Urban, S. N. Pavlou, J. E. Rivier, W. W. Vale, M. L. Dufau, J. D. Veldhuis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have used a new potent GnRH antagonist to assess the efficacy of suppression of gonadotropin secretion in healthy postmenopausal women at three different doses. The Nal-Glu antagonist produced significant suppression of immunoactive and bioactive LH at a 300 micrograms/kg dose throughout the 30-hr sampling interval with only minimal local (skin) histamine release. This increased potency and decreased skin reactivity of the Nal-Glu antagonist make it a drug with potential clinical use similar to the GnRH agonist, but with the advantage of immediate gonadotropin suppression.

Original languageEnglish (US)
Pages (from-to)302-309
Number of pages8
JournalTransactions of the Association of American Physicians
Volume101
StatePublished - 1988
Externally publishedYes

Fingerprint

Hormone Antagonists
Gonadotropins
Gonadotropin-Releasing Hormone
Skin
Peptides
Histamine Release
Pharmaceutical Preparations
2-naphthylalanyl-glutamic acid

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increased potency and sustained suppressive actions of a new gonadotropin-releasing hormone (GnRH) antagonist peptide in man. / Urban, Randall; Pavlou, S. N.; Rivier, J. E.; Vale, W. W.; Dufau, M. L.; Veldhuis, J. D.

In: Transactions of the Association of American Physicians, Vol. 101, 1988, p. 302-309.

Research output: Contribution to journalArticle

@article{9a980c8811724d70811430231e80fb6d,
title = "Increased potency and sustained suppressive actions of a new gonadotropin-releasing hormone (GnRH) antagonist peptide in man.",
abstract = "We have used a new potent GnRH antagonist to assess the efficacy of suppression of gonadotropin secretion in healthy postmenopausal women at three different doses. The Nal-Glu antagonist produced significant suppression of immunoactive and bioactive LH at a 300 micrograms/kg dose throughout the 30-hr sampling interval with only minimal local (skin) histamine release. This increased potency and decreased skin reactivity of the Nal-Glu antagonist make it a drug with potential clinical use similar to the GnRH agonist, but with the advantage of immediate gonadotropin suppression.",
author = "Randall Urban and Pavlou, {S. N.} and Rivier, {J. E.} and Vale, {W. W.} and Dufau, {M. L.} and Veldhuis, {J. D.}",
year = "1988",
language = "English (US)",
volume = "101",
pages = "302--309",
journal = "Transactions of the Association of American Physicians",
issn = "0066-9458",

}

TY - JOUR

T1 - Increased potency and sustained suppressive actions of a new gonadotropin-releasing hormone (GnRH) antagonist peptide in man.

AU - Urban, Randall

AU - Pavlou, S. N.

AU - Rivier, J. E.

AU - Vale, W. W.

AU - Dufau, M. L.

AU - Veldhuis, J. D.

PY - 1988

Y1 - 1988

N2 - We have used a new potent GnRH antagonist to assess the efficacy of suppression of gonadotropin secretion in healthy postmenopausal women at three different doses. The Nal-Glu antagonist produced significant suppression of immunoactive and bioactive LH at a 300 micrograms/kg dose throughout the 30-hr sampling interval with only minimal local (skin) histamine release. This increased potency and decreased skin reactivity of the Nal-Glu antagonist make it a drug with potential clinical use similar to the GnRH agonist, but with the advantage of immediate gonadotropin suppression.

AB - We have used a new potent GnRH antagonist to assess the efficacy of suppression of gonadotropin secretion in healthy postmenopausal women at three different doses. The Nal-Glu antagonist produced significant suppression of immunoactive and bioactive LH at a 300 micrograms/kg dose throughout the 30-hr sampling interval with only minimal local (skin) histamine release. This increased potency and decreased skin reactivity of the Nal-Glu antagonist make it a drug with potential clinical use similar to the GnRH agonist, but with the advantage of immediate gonadotropin suppression.

UR - http://www.scopus.com/inward/record.url?scp=0024153585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024153585&partnerID=8YFLogxK

M3 - Article

VL - 101

SP - 302

EP - 309

JO - Transactions of the Association of American Physicians

JF - Transactions of the Association of American Physicians

SN - 0066-9458

ER -